Goretti Duran

Goretti Duran

Auto-generated profile, based on publicly available information

Goretti Duran

Pharmacy Department, Clinical University Hospital of Santiago de Compostela (SERGAS), Santiago, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
AGAlvaro Goyanes
Alvaro Goyanes
CMChristine M. Madla
Christine M. Madla
AUAysha Umerji
Aysha Umerji
GPGoretti Duran Piñeiro
Goretti Duran Piñeiro
JMJose Maria Giraldez Montero
Jose Maria Giraldez Montero
ABAbdul W Basit
Abdul W Basit

7 February 2012 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
Ceres Fernández-RozadillaCeres Fernández-Rozadilla
Ceres Fernández-Rozadilla
JCJ B Cazier
J B Cazier
VMVictor Moreno
Victor Moreno
MCMarta Crous-Bou
Marta Crous-Bou
EGE Guinó
E Guinó
OCon behalf of the EPICOLON Consortium
on behalf of the EPICOLON Consortium

30 March 2011 in Pharmacogenomics
Verified
Journal Article
Closed access
MLMaria J Lamas
Maria J Lamas
GDGoretti Duran
Goretti Duran
EBEmilia Balboa
Emilia Balboa
BBBeatriz Bernardez
Beatriz Bernardez
MTManuel Touris
Manuel Touris
FBFrancisco Barros
Francisco Barros
Polymorphisms in the metabolism, detoxification or DNA repair pathways have been proposed as potential predictors of response to 5-fluorouracil and oxaliplatin. We have studied the predictive value of a set of germline genetic polymorphisms in metastatic colorectal cancer patients treated with mFolfox-6. A total of 72 patients, comprising 50 men (69.4%) and 22 women (30.6%), were included after the signing of an informed consent form. Median age was 65.5 years (range: 32-80). All participants received mFolfox-6. DNA was extracted from peripheral blood samples and genotyped by direct sequencing, SnapShot(®) and multiplex PCR techniques. Eight polymorphisms within six genes were investigated: TS 5´-UTR (variable number tandem repeat + G/C), TS 3´-UTR (TS1494del6); MTHFR C677T and A1298C; GSTP1 I105V; ERCC1 C118T; XPD Lys751Gln and XRCC1 Arg399Gln. Association was evaluated by univariate analysis, and Cox regression and Kaplan-Meier assessed survival. The local ethics committee approved the pharmacogenetic study protocol and all subjects signed an informed consent before participating in the study. The sample was in Hardy-Weinberg equilibrium. Only XPD Lys751Gln was found to be significantly associated with a favorable progression-free survival (PFS). Median PFS for XPD Lys751Gln patients (n = 33) was 16 months (95% CI: 9.2-22.7), 10 months (95% CI: 6.1-13.9) for Gln/Gln (n = 11) and 8 months (95% CI: 5.8-10.2) for Lys/Lys (n = 28), p = 0.019. The increased risk of progression was: 1.93 (95% CI: 1.13-13.30; p = 0.017) for Lys/Lys and 2.1 (95% CI: 1.01-4.22; p = 0.047) for Gln/Gln. Patients with one or two Val alleles of GSTP1 tended to a lower risk of progression compared with Ile/Ile homozygotes, p = 0.067. When XPD Lys751Gln and GSTP1 were analyzed jointly, patients who carried one or two favorable genotypes, XPD Lys751Gln and Val, had a longer median PFS: 11 months (95% CI: 7.4-14.6) compared with six (95% CI: 4.6-7.4) with unfavorable genotypes, p < 0.001. In metastatic colorectal cancer patients treated with mFolfox-6, the combination of haplotype XPD Lys751Gln-GSTP1 105Val seems to predict the risk of progression.

29 November 2019 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
SBSara Blanco‐Dorado
Sara Blanco‐Dorado
OMOlalla Maroñas
Olalla Maroñas
ALAna Latorre-Pellicer
Ana Latorre-Pellicer
MJMaría Teresa Rodríguez Jato
María Teresa Rodríguez Jato
ALAna López‐Vizcaíno
Ana López‐Vizcaíno
Anxo Fernández-FerreiroAnxo Fernández-Ferreiro
Anxo Fernández-Ferreiro

27 May 2010 in Pharmacogenomics
Verified
Journal Article
Closed access
EBEmilia Balboa
Emilia Balboa
GDGoretti Duran
Goretti Duran
MLMaria Jesus Lamas
Maria Jesus Lamas
AGAntonio Gomez-Caamaño
Antonio Gomez-Caamaño
CCCatuxa Celeiro-Muñoz
Catuxa Celeiro-Muñoz
FBFrancisco Barros
Francisco Barros
The identification of predictive markers of response to chemoradiotherapy treatment remains a promising approach for patient management in order to obtain the best response with minor side effects. Initially, we investigated whether the analysis of several markers previously studied and others not yet evaluated could predict response to 5-fluorouracil- and capecitabine-based neoadjuvant treatment in locally advanced rectal cancer. We studied germline and tumoral samples of 65 stage II/III rectal patients. A panel of pharmacogenetic markers was genotyped in paired peripheral blood samples and rectal cancer tumors. Our results seem to confirm the previously described association of thymidylate synthase and the prediction of chemoradiotherapy response in rectal cancer. However, it failed to confirm the clinical utility proposed for XRCC1, ERCC1, ERCC2, MTHFR and EGFR polymorphisms in blood/germline samples. Subsequently, with the aim of improving prediction of individual response and assessing the role of studied polymorphisms in response to treatment, we determined if changes in tumor response to these markers could predict clinical outcome. We found a high degree of changes between germline and tumor samples, mainly somatic mutations without microsatellite instability, and a minor frequency of loss-of-heterozygosity events. In tumoral samples, XRCC1 appeared to be significantly associated (p = 0.006) with downstaging of the tumor (odds ratio: 7.93; 95% CI: 1.03-60.83), but the increasing of TYMS low-expression alleles contradict the previous results observed in germline samples. The detection of somatic mutations in rectal cancer tumors led us to re-evaluate the utility of the tests performed in blood samples for these polymorphisms in rectal cancer. Furthermore, studies aimed at assessing the influence of pharmacogenetic markers in treatment response performed in blood samples should take into account the particular pattern of hypermutability present in each tumor type. We hypothesize that different patterns of hypermutability present in each tumor type would be related to the different results in association studies related to response to the treatment.

1 January 2012 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
MLMaria J. Lamas
Maria J. Lamas
GDGoretti Duran
Goretti Duran
AGAntonio Gomez
Antonio Gomez
EBEmilia Balboa
Emilia Balboa
UHUrbano Anido Herranz
Urbano Anido Herranz
FBFrancisco Barros
Francisco Barros